Studies show that an experimental drug can delay the onset of type 1 diabetes
June 17, 2019 Source: Xinhuanet
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Xinhua News Agency, Washington, June 15 - The National Institutes of Health recently issued a communique that a clinical trial funded by the agency showed that an experimental drug could delay the onset of age for people at high risk for type 1 diabetes by about 2 years.
The drug is called teplizumab and the clinical trial was carried out by the International Cooperation Organization's "Type 1 Diabetes Clinical Trial Network". The researchers recruited 76 subjects between the ages of 8 and 49, all of whom had type 1 diabetes, and the physical examination showed a higher risk of type 1 diabetes.
Subjects were randomized into two groups, with the treatment group receiving 14 days of drug injection and the control group receiving placebo. It was found that 72% of the control group developed type 1 diabetes during the trial, compared with only 43% in the treatment group. The median time to diagnosis of the control group was 2 years, and the treatment group was 4 years.
“This is the first time we have seen evidence that type 1 diabetes can delay the onset of disease through early preventive treatment,†said Lisa Spein, a researcher at the National Institute of Diabetes, Digestive Diseases and Nephrology, National Institutes of Health. These results are especially important for young people with relatives who have the disease because they may be at higher risk and benefit from early screening and treatment."
Type 1 diabetes is an autoimmune disease that occurs in children and adolescents. The patient's own immune system mistakenly attacks the beta cells in the pancreas, causing the latter to not secrete enough insulin to maintain optimal blood sugar levels. At present, there is no cure for type 1 diabetes, and patients must rely on insulin therapy for life.
The experimental drug teplizumab works mainly by inhibiting the immune system from destroying beta cells. Previous studies have shown that this drug can effectively slow beta cell loss in patients with newly diagnosed type 1 diabetes.
However, the researchers admit that the latest research still has some limitations, such as the small number of subjects, etc., more research is needed to verify the effectiveness and safety of the drug. Related results have been published in the New England Journal of Medicine.
Examination Nitrile Gloves,Nitrile Gloves,Powder Free Hand Gloves,Disposable Examination Nitrile Gloves
Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshimedicals.com